Gilead Sciences Expands Pipeline with Tubulis, Ouro, and Arcellx Deals

Acquisitions add ADC platform, autoimmune T-cell engager, and BCMA cell therapy to Gilead's portfolio

Apr. 7, 2026 at 11:08pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a collection of premium, polished objects arranged elegantly on a clean, monochromatic background, conceptually representing Gilead's strategic business moves to expand its pipeline and drive future growth.Gilead's strategic acquisitions strengthen its pipeline and position the company for potential growth through new product launches in the coming years.Foster City Today

Gilead Sciences executives outlined the company's rationale for three recently announced transactions—its proposed acquisitions of Tubulis, Ouro Medicines, and Arcellx. The deals are framed as additive to Gilead's already active late-stage pipeline and consistent with the company's business development strategy, with plans to focus next on integration and more routine transactions.

Why it matters

The transactions strengthen Gilead's portfolio across its three therapeutic areas of focus: virology, oncology, and inflammation. The additions of Tubulis' ADC platform, Ouro's BCMA x CD3 T-cell engager, and Arcellx's BCMA cell therapy provide potential pipeline catalysts as Gilead aims to maintain momentum with up to 10 new launches expected through 2027.

The details

The Tubulis acquisition brings an industry-leading ADC platform and a lead ovarian cancer program, TUB-040, which has shown promising Phase 1 data. The Ouro Medicines deal includes a BCMA x CD3 bispecific T-cell engager, OM-336, with potential in multiple autoimmune indications. The Arcellx acquisition consolidates the anito-cel BCMA cell therapy, which is nearing a potential FDA approval in fourth line-plus multiple myeloma.

  • Gilead expects the three transactions to close in the second quarter of 2026.
  • The company is preparing for a potential FDA approval of anito-cel in the fourth quarter of 2026.
  • Gilead plans to report first-quarter 2026 results on May 7.

The players

Gilead Sciences

A biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need, with a portfolio anchored by antiviral therapies for HIV and viral hepatitis.

Tubulis

A privately held, clinical-stage company with an industry-leading platform for antibody-drug conjugates (ADCs), including a lead ovarian cancer program, TUB-040.

Ouro Medicines

A privately held company with a portfolio focused on T-cell engagers for autoimmune conditions, including a BCMA x CD3 bispecific T-cell engager, OM-336.

Arcellx

A company that Gilead has collaborated with for over three years on the BCMA-directed CAR T-cell therapy anito-cel, which is nearing potential FDA approval in fourth line-plus multiple myeloma.

Daniel O'Day

Chairman and CEO of Gilead Sciences.

Got photos? Submit your photos here. ›

What they’re saying

“Even before the deals, 2026 was 'already an exciting moment' for the company, citing expectations for five Phase 3 updates across those areas and 'up to 10 ongoing and potential new launches through 2027.'”

— Daniel O'Day, Chairman and CEO

“The timing—three expected deal closings in the second quarter—'does not reflect any change' in confidence in the existing pipeline or a shift in M&A philosophy, but rather that the three companies 'met our high bar in quick succession.'”

— Daniel O'Day, Chairman and CEO

“The upfront valuation for Tubulis was 'supported by the ovarian cancer indications alone,' while also pointing to platform value and other assets.”

— Andrew Dickinson, CFO

What’s next

Gilead expects to focus next on integration of the acquired companies and 'more ordinary course business development transactions.'

The takeaway

Gilead's strategic acquisitions of Tubulis, Ouro Medicines, and Arcellx demonstrate the company's commitment to expanding its pipeline and maintaining momentum in its key therapeutic areas, positioning it for potential growth through new product launches in the coming years.